Mid-Year Report

HOSPIRA, INC. for HOSPIRA INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$40,000

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
Mid-Year Report (this page) Aug 13, 2007 $40,000 Replaced
Mid-Year Report Aug 13, 2007 $40,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

HR 1038 / S 623: "Access to Life Saving Medicines Act", Support Biogenerics. In the Senate: "The Biologics Price Competition and Innovation Act of 2007", Supports Biogenerics. S 1082: "The FDA Revitalization Act of 2007", Reauthorizes prescription drug and medical device user fee legislation.

LobbyistCovered position, as disclosed
JULIANA REED N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1038 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.